Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq Omx Stockholm
11/24/2020 11/25/2020 11/26/2020 11/27/2020 11/30/2020 Date
41.3 41.8 40.6 40.7 40.1 Last
40684 41087 50082 19882 30656 Volume
+1.47% +1.21% -2.87% +0.25% -1.47% Change
Financials
Sales 2021 19,5 M 2,29 M 2,29 M
Net income 2021 -32,5 M -3,82 M -3,82 M
Net cash position 2021 6,50 M 0,76 M 0,76 M
P/E ratio 2021 -29,0x
Yield 2021 -
Sales 2022 45,5 M 5,35 M 5,35 M
Net income 2022 -17,0 M -2,00 M -2,00 M
Net Debt 2022 18,0 M 2,12 M 2,12 M
P/E ratio 2022 -54,9x
Yield 2022 -
Capitalization 1 134 M 132 M 133 M
EV / Sales 2021 57,8x
EV / Sales 2022 25,3x
Nbr of Employees 21
Free-Float 70,3%
More Financials
Company
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates... 
More about the company
Notations Surperformance© of Biovica International AB (publ)
Trading Rating : Investor Rating :
More Ratings
All news about BIOVICA INTERNATIONAL AB (PUBL)
11/23BIOVICA INTERNATIONAL : DiviTum®TKa included in new UK breast cancer study
AQ
11/20BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTum®TKa r..
AQ
11/19BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTum®TKa as an early an..
AQ
11/18BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
AQ
11/17BIOVICA INTERNATIONAL : DiviTum®TKa Monitoring Capabilities Confirmed in SWOG St..
AQ
11/13BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
AQ
10/30BIOVICA INTERNATIONAL : FDA resource reallocation impacts DiviTum®TKa timeline
AQ
10/23BIOVICA INTERNATIONAL : DiviTum®TKa in four posters at SABCS
AQ
09/25BIOVICA INTERNATIONAL : completes 510(k) submission for DiviTum®TKa to the FDA
AQ
08/27BIOVICA INTERNATIONAL : Bulletin from the annual general meeting in Biovica
AQ
08/27BIOVICA Q1 INTERIM REPORT : May-July 2020/2021
AQ
More news
News in other languages on BIOVICA INTERNATIONAL AB (PUBL)

- No features available -

More news
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 31,00 SEK
Last Close Price 40,10 SEK
Spread / Highest target -22,7%
Spread / Average Target -22,7%
Spread / Lowest Target -22,7%
EPS Revisions
Managers
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors